Cargando…

Re-administration of immune checkpoint inhibitors for patients with non-small cell lung cancer

Detalles Bibliográficos
Autor principal:	Hakozaki, Taiki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742624/ https://www.ncbi.nlm.nih.gov/pubmed/36519026 http://dx.doi.org/10.21037/tlcr-22-717

Ejemplares similares

Immune checkpoint inhibitors for patients with gene-rearranged non-small cell lung cancer
por: Uehara, Yuji, et al.
Publicado: (2022)

Re-challenging immune checkpoint inhibitor in a patient with advanced non-small cell lung cancer: a case report
por: Hakozaki, Taiki, et al.
Publicado: (2018)

Switching administration of anti‐PD‐1 and anti‐PD‐L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non‐small cell lung cancer: Case series and literature review
por: Kitagawa, Shingo, et al.
Publicado: (2020)

Efficacy of second-line chemotherapy after immunotherapy in advanced non-small cell lung cancer
por: Hirata, Tsuyoshi, et al.
Publicado: (2023)

PD-L1 expression in small cell lung cancer: should we designate it for assignment?
por: Hakozaki, Taiki
Publicado: (2021)

Immune checkpoint inhibitor re-challenge in patients with advanced non-small cell lung cancer
por: Niki, Maiko, et al.
Publicado: (2018)

For which lung cancer patients is re-administration of immune checkpoint inhibitors effective?
por: Sasaki, Takanobu, et al.
Publicado: (2021)

Immune checkpoint inhibitors and driver oncogenes in non-small cell lung cancer
por: Miura, Yosuke, et al.
Publicado: (2019)

Association between the baseline tumor size and outcomes of patients with non-small cell lung cancer treated with first-line immune checkpoint inhibitor monotherapy or in combination with chemotherapy
por: Uehara, Yuji, et al.
Publicado: (2022)

Safety and efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients with preexisting antinuclear antibodies: a retrospective cohort study
por: Zhang, Dongming, et al.
Publicado: (2022)

TTF-1 and immune checkpoint therapy in non-small cell lung cancer
por: Gumbleton, Matthew, et al.
Publicado: (2023)

Is smoking history the truly best biomarker for immune checkpoint inhibitor treatment in advanced non-small cell lung cancer?
por: Pirker, Robert
Publicado: (2018)

Chemotherapy and immune checkpoint inhibitor combination, a new standard in squamous non-small cell lung cancer?
por: Travert, Camille, et al.
Publicado: (2020)

Immune checkpoint inhibitors for non-small cell lung cancer patients on steroid or non-steroidal anti-inflammatory drugs treatment—therapeutic indication or therapeutic efficacy?
por: Kawase, Akikazu
Publicado: (2022)

Tumor Immunology and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
por: Jung, Chi Young, et al.
Publicado: (2018)

Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer
por: Qiu, Zhenbin, et al.
Publicado: (2019)

Perioperative Therapy for Non-Small Cell Lung Cancer with Immune Checkpoint Inhibitors
por: Soh, Junichi, et al.
Publicado: (2021)

Predictive Markers for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
por: Ushio, Ryota, et al.
Publicado: (2022)

Theory Meets Practice for Immune Checkpoint Blockade in Small-Cell Lung Cancer
por: Riess, Jonathan W., et al.
Publicado: (2016)

The role of laboratory tests as a prognostic marker for immune-checkpoint therapy in non-small cell lung cancer
por: Ashok Kumar, Prashanth, et al.
Publicado: (2023)

Advances in immunotherapy for stage III non-small cell lung cancer: moving immune checkpoint inhibitors to the front lines concurrently with chemoradiotherapy?
por: Hida, Toyoaki, et al.
Publicado: (2020)

Metabolomics to Assess Response to Immune Checkpoint Inhibitors in Patients with Non-Small-Cell Lung Cancer
por: Ghini, Veronica, et al.
Publicado: (2020)

Utomilumab in Patients With Immune Checkpoint Inhibitor-Refractory Melanoma and Non-Small-Cell Lung Cancer
por: Hong, David S., et al.
Publicado: (2022)

Neoadjuvant immunotherapy in resectable non-small cell lung cancer at a checkpoint
por: Faltermeier, Claire M., et al.
Publicado: (2021)

Efficacy of first‐line immune checkpoint inhibitors in patients with advanced NSCLC with KRAS , MET , FGFR , RET , BRAF , and HER2 alterations
por: Uehara, Yuji, et al.
Publicado: (2022)

Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment
por: El-Osta, Hazem, et al.
Publicado: (2016)

Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer
por: Lim, Sung Won, et al.
Publicado: (2019)

Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects
por: Tang, Shengjie, et al.
Publicado: (2022)

Efficacy and predictors of rechallenge with immune checkpoint inhibitors in non‐small cell lung cancer
por: Takahara, Yutaka, et al.
Publicado: (2022)

Resistance to immune checkpoint inhibitors in KRAS-mutant non-small cell lung cancer
por: Li, Yunchang, et al.
Publicado: (2022)

Blood Biomarkers of Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
por: Alfranca, Yolanda Lage, et al.
Publicado: (2022)

Role of Neoadjuvant Immune Checkpoint Inhibitors in Resectable Non-Small Cell Lung Cancer
por: Riano, Ivy, et al.
Publicado: (2023)

Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer
por: Zhou, Kexun, et al.
Publicado: (2023)

Immune checkpoint inhibitors for the treatment of non-small cell lung cancer brain metastases
por: Wei, Yuxi, et al.
Publicado: (2023)

Immune checkpoint inhibitors for every patient with non-small cell lung cancer? Update on immunotherapy in patients with lung cancer
por: Vansteenkiste, Johan F
Publicado: (2018)

Immune checkpoint inhibitors in penile cancer
por: Buonerba, Carlo, et al.
Publicado: (2021)

Quantitative spatial profiling of PD-1/PD-L1 interaction in patients with cancer
por: Hakozaki, Taiki
Publicado: (2023)

Recent advances in immune checkpoint inhibitors for non-small lung cancer treatment
por: Altaf, Reem, et al.
Publicado: (2022)

Utility of immune checkpoint inhibitors in non‐small‐cell lung cancer patients with poor performance status
por: Kano, Hirohisa, et al.
Publicado: (2020)

The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients
por: Zhai, Xiaoyang, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_nk12ghhknkpo61tdr62gov6phv